Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Generic Vancocin, An Advisory Committee Role Reversal

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will essentially play the part of a sponsor during the Aug. 4 pharmaceutical science panel meeting, arguing for favorable approval standards, while the brand sponsor, ViroPharma, will play the role of skeptic.

You may also be interested in...



Generic Vancocin Gets Clear Approval Path From Advisory Committee

Pharmaceutical science panel unanimously endorses FDA's proposed dissolution approach.

Generic Vancocin Gets Clear Approval Path From Advisory Committee

Pharmaceutical science panel unanimously endorses FDA's proposed dissolution approach.

ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition

The biotech's HAE drug exceeded sales expectations during the second quarter, but FDA cites the company for misleading promotion.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel